Cite
An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay.
MLA
Torales, Julio, et al. “An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an Interim Analysis of a Phase III, Parallel Group, Randomized, Double-Blind, Active-Controlled Immunobridging Study in Paraguay.” Vaccine, vol. 41, no. 1, Jan. 2023, pp. 109–18. EBSCOhost, https://doi.org/10.1016/j.vaccine.2022.10.030.
APA
Torales, J., Cuenca-Torres, O., Barrios, L., Armoa-Garcia, L., Estigarribia, G., Sanabria, G., Lin, M.-Y., Antonio Estrada, J., Estephan, L., Cheng, H.-Y., Chen, C., Janssen, R., & Lien, C.-E. (2023). An evaluation of the safety and immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled immunobridging study in Paraguay. Vaccine, 41(1), 109–118. https://doi.org/10.1016/j.vaccine.2022.10.030
Chicago
Torales, Julio, Osmar Cuenca-Torres, Laurentino Barrios, Luis Armoa-Garcia, Gladys Estigarribia, Gabriela Sanabria, Meei-Yun Lin, et al. 2023. “An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an Interim Analysis of a Phase III, Parallel Group, Randomized, Double-Blind, Active-Controlled Immunobridging Study in Paraguay.” Vaccine 41 (1): 109–18. doi:10.1016/j.vaccine.2022.10.030.